gefapixant Archives -

gefapixant

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials,

Bayer’s pipeline takes a hit as it drops eliapixant

https://pharmaphorum.com/news/bayers-pipeline-takes-a-hit-as-it-drops-eliapixant/

The FDA has issued a complete response letter (CRL) to Merck & Co’s gefapixant candidate for refractory chronic

FDA stifles Merck’s cough drug gefapixant, asking for more data

https://pharmaphorum.com/news/fda-stifles-mercks-cough-drug-gefapixant-asking-for-more-data/

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it

Bayer’s eliapixant hits the right notes in PAGANINI cough study

https://pharmaphorum.com/news/bayers-eliapixant-hits-the-right-notes-in-paganini-cough-study/

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase

Chasing Merck & Co, Bayer builds case for cough drug eliapixant

https://pharmaphorum.com/news/chasing-merck-bayer-builds-case-for-cough-drug-eliapixant/

Merck & Co/MSD’s experimental drug gefapixant has improved the frequency of coughing in a pair of phase 3

Merck’s chronic cough drug gefapixant clears phase 3 test

https://pharmaphorum.com/news/mercks-chronic-cough-drug-gefapixant-clears-phase-3-test/

gefapixant